Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 7,689 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $30.03, for a total value of $230,900.67. Following the transaction, the senior vice president now directly owns 27,265 shares in the company, valued at $818,767.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Santiago Arroyo also recently made the following trade(s):
- On Tuesday, January 21st, Santiago Arroyo sold 1,235 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $30.08, for a total value of $37,148.80.
NASDAQ:MNTA opened at $31.88 on Friday. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of -14.69 and a beta of 2.01. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $32.37. The business’s fifty day moving average price is $26.17 and its 200 day moving average price is $17.38.
Large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Momenta Pharmaceuticals by 53.0% during the second quarter. Bank of America Corp DE now owns 177,782 shares of the biotechnology company’s stock valued at $2,215,000 after buying an additional 61,579 shares during the period. Morgan Stanley raised its position in Momenta Pharmaceuticals by 709.7% during the second quarter. Morgan Stanley now owns 460,537 shares of the biotechnology company’s stock valued at $5,733,000 after buying an additional 403,661 shares during the period. UBS Asset Management Americas Inc. raised its position in Momenta Pharmaceuticals by 19.8% during the second quarter. UBS Asset Management Americas Inc. now owns 59,794 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 9,876 shares during the period. Nuveen Asset Management LLC acquired a new position in Momenta Pharmaceuticals during the second quarter valued at $4,751,000. Finally, Peregrine Capital Management LLC raised its position in Momenta Pharmaceuticals by 3.4% during the third quarter. Peregrine Capital Management LLC now owns 832,627 shares of the biotechnology company’s stock valued at $10,791,000 after buying an additional 27,377 shares during the period. 97.03% of the stock is currently owned by hedge funds and other institutional investors.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Recommended Story: Mutual Funds
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.